Institute, Amsterdam), Stefano Piccolo (University of Padua School of Medicine, Padua) and Joan Seoane (Vall d'Hebron Institute of Oncology, Barcelona). Their expertise, together with that of the rest of the Editorial Board (http://febs.onlinelibrary.wiley.com/ hub/journal/10.1002/(ISSN)1878-0261/editorial-board. html), will help shape the future development of the journal.
In the new Open Access format, we expect the editorial team to continue to apply the same rigorous standards of peer review and acceptance criteria, ensuring that the journal remains the high-quality publication we have come to value greatly.
We very much hope that you share our excitement for these new developments for Molecular Oncology and if you have any questions, please do not hesitate to contact us.
Finally, we would like to thank Elsevier for the continuous support and encouragement we received during the past ten years. In particular, we would like to thank Adrian Klinkenberg, Carl Schwarz, Lucia Muñoz Franco and Olaf Meesters with whom we worked closely together for various periods of time during the development of the journal. Also, our thanks extend to Mary Purton from FEBS Press as well as members of the Wiley team for the much-appreciated help and advice received during the transition period.
